Edgar Filing: AmpliPhi Biosciences Corp - Form 4

AmpliPhi Bi Form 4	iosciences Corp								
January 31, 2	2017								
FORM	4 UNITED	STATES					COMMISSIO	N OMB	PPROVAL 3235-0287
Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may com <i>See</i> Instr 1(b).	ger o 16. or Filed pur ons tinue. Section 17(suant to S a) of the l	F CHAI Section	SECUI 16(a) of th Jtility Hol	BENEF RITIES ne Securi ding Cor	ICIAL OV	WNERSHIP OF nge Act of 1934, of 1935 or Secti 940	Estimated burden hou response	January 31, 2005 average urs per
(Print or Type]	Responses)								
1. Name and A BILINSKY	Address of Reporting IGOR	Person <u>*</u>	Symbol	er Name an Phi Biosci		Trading	5. Relationship o Issuer	of Reporting Per eck all applicabl	
(Last) (First) (Middle) C/O AMPLIPHI BIOSCIENCES CORPORATION, 3579 VALLEY CENTRE DRIVE, SUITE 100			3. Date of Earliest Transaction (Month/Day/Year) 01/30/2017			Director 10% Owner X Officer (give title Other (specify below) below) Chief Operating Officer			
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip)	Tat	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Reminder: Rep	port on a separate line	for each cl	ass of sec	urities bene	Perso inform requir	ns who res nation cont red to respo ays a curre	or indirectly. spond to the colle ained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)
	Tab					posed of, or convertible s	Beneficially Owned securities)	1	

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: AmpliPhi Biosciences Corp - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A Disposed of (Instr. 3, 4, a 5)	(D)	(Month/Day,	/Year)	(Instr. 3 and	4)
				Code V	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 0.46	01/30/2017		А	247,322		<u>(1)</u>	01/29/2027	Common Stock	247,322

Reporting Owners

Reporting Owner Name / Address	Relationships					
FB	Director	10% Owner	Officer	Other		
BILINSKY IGOR C/O AMPLIPHI BIOSCIENCES CORPORATION 3579 VALLEY CENTRE DRIVE, SUITE 100 SAN DIEGO, CA 92130			Chief Operating Officer			
Signatures						

/s/ Igor P.	
Bilinsky	01/30/2017
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/4th of the shares subject to the option vest on January 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.